Lotus Pharmaceutical Co Ltd
TWSE:1795

Watchlist Manager
Lotus Pharmaceutical Co Ltd Logo
Lotus Pharmaceutical Co Ltd
TWSE:1795
Watchlist
Price: 263.5 TWD -0.94% Market Closed
Market Cap: 70.1B TWD
Have any thoughts about
Lotus Pharmaceutical Co Ltd?
Write Note

Lotus Pharmaceutical Co Ltd
EPS (Diluted)

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Lotus Pharmaceutical Co Ltd
EPS (Diluted) Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company EPS (Diluted) CAGR 3Y CAGR 5Y CAGR 10Y
Lotus Pharmaceutical Co Ltd
TWSE:1795
EPS (Diluted)
NT$16
CAGR 3-Years
43%
CAGR 5-Years
47%
CAGR 10-Years
N/A
Y
YungShin Global Holding Corp
TWSE:3705
EPS (Diluted)
NT$3
CAGR 3-Years
13%
CAGR 5-Years
9%
CAGR 10-Years
3%
Formosa Laboratories Inc
TWSE:4746
EPS (Diluted)
NT$3
CAGR 3-Years
-33%
CAGR 5-Years
14%
CAGR 10-Years
1%
ScinoPharm Taiwan Ltd
TWSE:1789
EPS (Diluted)
NT$0
CAGR 3-Years
26%
CAGR 5-Years
9%
CAGR 10-Years
-6%
S
SCI Pharmtech Inc
TWSE:4119
EPS (Diluted)
NT$4
CAGR 3-Years
N/A
CAGR 5-Years
-11%
CAGR 10-Years
2%
Standard Chem & Pharm Co Ltd
TWSE:1720
EPS (Diluted)
NT$4
CAGR 3-Years
7%
CAGR 5-Years
18%
CAGR 10-Years
10%
No Stocks Found

Lotus Pharmaceutical Co Ltd
Glance View

Market Cap
69.9B TWD
Industry
Pharmaceuticals

Lotus Pharmaceutical Co., Ltd., nestled at the intersection of innovation and healthcare, has carved a niche in the competitive pharmaceuticals landscape. Founded in Taiwan, Lotus has evolved into a prominent player, with a strategic focus on the development, manufacturing, and distribution of high-barrier generic drugs and specialty pharmaceuticals. Its journey began as a local pharmaceutical manufacturer but rapidly expanded its horizons through well-timed acquisitions and partnerships. These strategic moves have not only broadened its portfolio but also fortified its foothold in various international markets. The company leverages cutting-edge research and development capabilities to produce cost-effective alternatives to branded medications, which require significant expertise to replicate due to complex manufacturing processes and stringent regulatory requirements. Lotus’s operations hinge on its ability to navigate the intricacies of pharmaceutical regulations and patent landscapes, enabling it to introduce generics as soon as original drug patents expire. This strategic agility allows the company to capture market share quickly and maximize its revenue potential. Lotus Commercializes its products primarily in Asia while also extending its reach to North America and Europe through a network of collaborations and partnerships. Its robust portfolio spans several therapeutic areas, including oncology, central nervous system disorders, and cardiovascular diseases, where the demand for affordable medications is acute. As a result, Lotus not only generates substantial revenue but also plays a pivotal role in enhancing healthcare accessibility and affordability across the globe.

Intrinsic Value
384.39 TWD
Undervaluation 31%
Intrinsic Value
Price

See Also

What is Lotus Pharmaceutical Co Ltd's EPS (Diluted)?
EPS (Diluted)
16.5 TWD

Based on the financial report for Sep 30, 2024, Lotus Pharmaceutical Co Ltd's EPS (Diluted) amounts to 16.5 TWD.

What is Lotus Pharmaceutical Co Ltd's EPS (Diluted) growth rate?
EPS (Diluted) CAGR 5Y
47%

Over the last year, the EPS (Diluted) growth was 11%. The average annual EPS (Diluted) growth rates for Lotus Pharmaceutical Co Ltd have been 43% over the past three years , 47% over the past five years .

Back to Top